Acute respiratory distress syndrome (ARDS) has been associated with considerable morbidity and mortality, even before the COVID-19 pandemic hit. For the most part, ARDS management is limited to ...

Inhaled sevoflurane significantly reduced ventilator-free days and 90-day survival versus IV propofol in moderate to severe ARDS. Inhaled volatile sedatives grew in popularity for prolonged use in ...

ARDS is a life-threatening lung condition causing severe breathing failure. New research shows AI could personalize ...

Please provide your email address to receive an email when new articles are posted on . Pulmonary hypertension plus acute respiratory distress syndrome resulted in poor hospital outcomes. Odds for ...

Drawing from research on sepsis and complement biology, they developed the monoclonal antibody vilobelimab to block overactive inflammatory responses in patients with severe inflammatory diseases ...

Deaths from acute respiratory distress syndrome (ARDS) and sepsis spiked in the US during the COVID pandemic, and subsequently declined, according to new data presented at the American College of ...

In a recent study posted to the medRxiv* preprint server, researchers compared the pathophysiology of coronavirus disease 2019 (COVID-19) and bacterial sepsis-induced acute respiratory distress ...

Acute respiratory distress syndrome, also known as ARDS, is a common killer among critically ill patients hospitalized with COVID-19. But even if they survive, it’s a long road to recovery. Patients ...

Acute respiratory distress syndrome (ARDS) is a potentially fatal condition where the lungs cannot provide enough oxygen to the body's vital organs. The condition, otherwise known as acute lung injury ...

Acute respiratory distress syndrome (ARDS) remains a major challenge in critical care, with mortality rates often exceeding 35–40%. Mechanical ...